Patient insights for clinical development
Volv Global accelerates and de-risks clinical development strategies much earlier in the pharma development lifecycle, improving planning robustness and efficiency through better understanding of patients cohorts and diseases.

De-risk clinical strategy
Identify a cohort more precisely to establish better clinical development strategies much earlier in the development lifecycle.
Find more patients, earlier, and quicker
Understand disease and disease progression to find the right patients at the right point in the patient journey. Identify patient clusters to support trial site selection.
Expand disease understanding
Elucidate disease heterogeneity and identify novel endpoints to signpost new biomarkers to optimise protocol design.
Overcome data gaps
Use advance machine learning techniques to overcome issues of unstructured data, data sparsity and bias in data sources.